Suzhou Fushilai Pharmaceutical Co., Ltd. (SHE:301258)

Market Cap	2.35B -23.6%
Revenue (ttm)	394.29M -9.7%
Net Income	6.60M -89.0%
EPS	0.07 -88.8%
Shares Out	88.59M
PE Ratio	355.93
Forward PE	n/a
Dividend	0.22 (0.83%)
Ex-Dividend Date	May 29, 2026

Volume	1,438,700
Open	26.57
Previous Close	26.68
Day's Range	25.72 - 26.87
52-Week Range	21.78 - 38.31
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About SHE:301258

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; L-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonst...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 540
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301258

Financial Performance

In 2025, SHE:301258's revenue was 432.73 million, an increase of 0.76% compared to the previous year's 429.47 million. Earnings were 64.29 million, an increase of 291.89%.

Data Sources: S&P Global Market Intelligence and Alpha Vantage

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Alpha Vantage.

Last checked:

Oct 14, 2026

Data Sources Report a data error